CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage; 68Ga-Nota-MSA, indicated for cardiovascular disease diagnosis, currently under Phase 2 clinical stage; 99mTc-MSA-ICG, indicated for lymphoscintigraphy SLN mapping, currently under Phase 1 clinical stage; and 68Ga-NGUL, indicated for prostate cancer diagnosis, currently under Phase 2 clinical stage. It is also involved in the development of preclinical stage pipeline comprising 68 Ga-FAP, indicated for solid tumors diagnosis; 225 Ac-FAP, indicated for solid tumors radiotherapy; and peptide-based radioligand therapy and antibody-radionuclide conjugates for undisclosed indications. The company was founded in 2010 and is headquartered in Seoul, South Korea.
Metrics to compare | 308430 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship308430PeersSector | |
---|---|---|---|---|
P/E Ratio | −42.4x | −2.0x | −0.5x | |
PEG Ratio | - | 0.03 | 0.00 | |
Price/Book | 11.0x | 1.2x | 2.6x | |
Price / LTM Sales | 120.5x | 1.8x | 3.3x | |
Upside (Analyst Target) | - | 48.2% | 42.8% | |
Fair Value Upside | Unlock | 10.3% | 6.5% | Unlock |